Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and...
Comments: Innovative Medicine sales were up 1% to $13.6 billion in the quarter. DARZALEX (daratumumab) sales were $2.7 billion, up 19%. ERLEADA (apalutamide) sales were $689 million, up 27%. CARVYKTI (ciltacabtagene autoleucel) sales were $157 million, up from $72 million in 1Q23. TECVAYLI (teclistamab-cqyv) sales were $133 million, up from 63 million in 1Q23. Other Oncology sales were $178 million, up 80% in the quarter. UPTRAVI (selexipag) sales were up 29% to $468 million and OPSUMIT (macitentan) sales were up 19% to $524 million. TREMFYA (guselkumab) sales were up 26% to $808 million. SPRAVATO (esketamine) sales were up 72% to $225 million. COVID-19 Vaccine sales were down 97% to $25 million. XARELTO sales were down 10% to $518 million. REMICADE sales were down 11% to $434 million. ZYTIGA sales were down 26% to $181 million. CONCERTA sales were down 14% to $177 million.
SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months.1 These data were presented today at an Oral Presentation Session (Abstract #P2-07) at the 2024 American Urological Association Annual Meeting AUA, May 3-6, 2024, in San Antonio, Texas.
LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune...
TORONTO, Aug. 9, 2023 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance (NOC) authorizing the use of ERLEADA® (apalutamide) in an additional strength of a 240mg tablet. ERLEADA® 240 mg is now the only once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved by Health Canada for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) as well as patients with non-metastatic castration-resistant prostate cancer (nmCRPC).1
HORSHAM, Pa., April 3, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
The United States’ Food and Drug Administration (FDA) has approved twice-a-year injections and tablets for treating HIV in adults with multi-drug resistant infection.
A group of plaintiffs, including J&J’s Janssen unit and the Sloan Kettering Institute for Cancer Research, filed a lawsuit against Aurobindo on Thursday accusing it of applying to market an Erleada copycat before five patents are up.
FDA Confirms Para IV Patent Litigation for Apalutamide tablets.
SAN FRANCISCO, Feb. 14, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. These findings will be presented during the American Society of Clinical Oncology's Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19, 2022.